The U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee voted unanimously to approve two antibacterial treatments for methicillin-resistant Staphylococcus aureus skin infections.
The treatments are Sivextro (tedizolid phosphate), from Cubist Pharmaceuticals, and Dalvance (vancomycin-linezolid combination), from Durata Therapeutics. Sivextro is a daily oral or intravenous drug, while Dalvance is a weekly IV treatment.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Both drugs successfully completed phase III clinical trials to be considered for approval, according to a Medscape report. However, the drugs will be subject to postmarket safety monitoring, as concerns raised during public hearings included a lack of diversity in the study populations and use of drug-to-drug efficacy comparisons instead of drug-to-disease efficacy comparisons.
More Articles on Infection Control & Clinical Quality:
Lucrative Treatments Overlooked for Lists of Unnecessary Procedures
Direct Patient Education Improves Adherence to Drug-Use Guidelines
3 Tips to Prevent Cardiac SSIs From Cleveland Clinic